Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2016

View Archived Issues

Data presented on brentuximab vedotin in germ-cell tumors

Daiichi Sankyo divulges new S1PL inhibitors

Aryl-sulfonamides as isoform-selective inhibitors of Nav1.7

A first-in-human study of RG-7666

Allied-Bristol Life Sciences launches new subsidiary iBeCa Therapeutics

Microlin Bio to acquire Marina's nucleic acid therapeutic assets

Mologen announces extension of TEACH study

Vraylar now available in the U.S. as treatment of adults with bipolar mania and schizophrenia

FDA grants breakthrough therapy designation for NI-0501 for the treatment of primary HLH

MP-376 receives QIDP designation

Sanofi and DiCE Molecules announce research collaboration

BioBlast Pharma announces positive final results from HOPEMD phase II study

Istituto Europeo di Oncologia patents KDM1A inhibitors

Synergistic anticancer effects of GEN-1 combined with Avastin and Doxil in preclinical studies

Merck & Co. discloses DGAT-2 inhibitors

AstraZeneca exercises option to acquire rights to Orexo's OX-CLI program

Nippon Shinyaku develops JAK1 inhibitors

TES Pharma presents ACMSD inhibitors

Amgen divulges Mcl-1 inhibitors

Grant supports City of Hope's development of treatment for Canavan disease

Cleveland BioLabs updates progress of entolimod pre-EUA review

MDxHealth launches SelectMDx for Prostate Cancer test in U.S.

Proof of concept achieved in phase IIa trial of VTP-43742 for psoriasis

VESTRI safety study of Advair Diskus in children meets primary endpoint

FDA approves Kovaltry for hemophilia A in children and adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...